Literature DB >> 10074159

Substitutions in the receptor-binding domain of the avian sarcoma and leukosis virus envelope uncouple receptor-triggered structural rearrangements in the surface and transmembrane subunits.

R Damico1, L Rong, P Bates.   

Abstract

The retrovirus avian sarcoma and leukosis virus (ASLV) enters cells via pH-independent membrane fusion. This reaction is catalyzed by the viral glycoprotein Env, composed of a membrane-distal subunit, SU, and a membrane-anchored subunit, TM. Previous mutational analysis of a variable region, central within the SU subunit, indicates that this region constitutes part of the receptor-binding domain for subgroup A envelope (EnvA) and furthermore that basic residues (R210, R213, R223, R224, and K227) within this region are critical determinants of efficient ASLV infection. Substitutions of these basic residues exert effects on both receptor binding and postbinding events in EnvA-mediated entry. In this study, we performed biochemical analysis of the EnvA protein from three of the receptor-binding domain mutants (R213A/K227A, R213A/R223A/R224A, and R213S) to define the role of this domain in early molecular events in the entry pathway. Protease sensitivity assays demonstrated that receptor binding was sufficient to trigger conformational changes in the SU subunit of mutants R213A/K227A and R213S similar to those in the wild-type EnvA, while R213A/R223A/R224A was constitutively sensitive to protease. In contrast, all three receptor-binding domain mutants disrupted receptor-triggered conversion of EnvA to an active, membrane-binding conformation as assessed by liposome flotation assays. Our results demonstrate that mutations in the receptor-binding site can dissociate receptor-triggered conformational changes in the SU subunit from membrane binding. Furthermore, they suggest that communication between the receptor-binding subunit, SU, and the fusogenic subunit, TM, is crucial for efficient activation of the fusogenic state of EnvA. Analysis of these mutants continues earlier observations that binding to the cellular receptor provides the trigger for efficient activation of this pH-independent viral envelope protein.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074159      PMCID: PMC104069     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Subunit structure of the glycoprotein complex of avian tumor virus.

Authors:  R N Leamnson; M S Halpern
Journal:  J Virol       Date:  1976-06       Impact factor: 5.103

2.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

3.  In vitro generation of an HTLV-III variant by neutralizing antibody.

Authors:  M Robert-Guroff; M S Reitz; W G Robey; R C Gallo
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

4.  Molecular basis of host range variation in avian retroviruses.

Authors:  A J Dorner; J P Stoye; J M Coffin
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

5.  Determinants for receptor interaction and cell killing on the avian retrovirus glycoprotein gp85.

Authors:  A J Dorner; J M Coffin
Journal:  Cell       Date:  1986-05-09       Impact factor: 41.582

6.  env genes of avian retroviruses: nucleotide sequence and molecular recombinants define host range determinants.

Authors:  C A Bova; J P Manfredi; R Swanstrom
Journal:  Virology       Date:  1986-07-30       Impact factor: 3.616

7.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.

Authors:  G I Evan; G K Lewis; G Ramsay; J M Bishop
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

8.  Production and characterization of a soluble, active form of Tva, the subgroup A avian sarcoma and leukosis virus receptor.

Authors:  J W Balliet; J Berson; C M D'Cruz; J Huang; J Crane; J M Gilbert; P Bates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

9.  Cell fusion by Semliki Forest, influenza, and vesicular stomatitis viruses.

Authors:  J White; K Matlin; A Helenius
Journal:  J Cell Biol       Date:  1981-06       Impact factor: 10.539

10.  Inhibition of vesicular stomatitis virus infection by spike glycoprotein. Evidence for an intracellular, G protein-requiring step.

Authors:  D K Miller; J Lenard
Journal:  J Cell Biol       Date:  1980-02       Impact factor: 10.539

View more
  13 in total

1.  A fifteen-amino-acid TVB peptide serves as a minimal soluble receptor for subgroup B avian leukosis and sarcoma viruses.

Authors:  Daniel J Knauss; John A T Young
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  G100R mutation within 4070A murine leukemia virus Env increases virus receptor binding, kinetics of entry, and viral transduction efficiency.

Authors:  Chi-Wei Lu; Lucille O'Reilly; Monica J Roth
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Premature activation of the paramyxovirus fusion protein before target cell attachment with corruption of the viral fusion machinery.

Authors:  Shohreh F Farzan; Laura M Palermo; Christine C Yokoyama; Gianmarco Orefice; Micaela Fornabaio; Aurijit Sarkar; Glen E Kellogg; Olga Greengard; Matteo Porotto; Anne Moscona
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

4.  Identification of key residues in subgroup A avian leukosis virus envelope determining receptor binding affinity and infectivity of cells expressing chicken or quail Tva receptor.

Authors:  S L Holmen; D C Melder; M J Federspiel
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

5.  Soluble forms of the subgroup A avian leukosis virus [ALV(A)] receptor Tva significantly inhibit ALV(A) infection in vitro and in vivo.

Authors:  S L Holmen; D W Salter; W S Payne; J B Dodgson; S H Hughes; M J Federspiel
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Expanded tropism and altered activation of a retroviral glycoprotein resistant to an entry inhibitor peptide.

Authors:  Sean M Amberg; Robert C Netter; Graham Simmons; Paul Bates
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate.

Authors:  Robert C Netter; Sean M Amberg; John W Balliet; Mark J Biscone; Arwen Vermeulen; Laurie J Earp; Judith M White; Paul Bates
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

8.  Evolutionary pressure of a receptor competitor selects different subgroup a avian leukosis virus escape variants with altered receptor interactions.

Authors:  Deborah C Melder; V Shane Pankratz; Mark J Federspiel
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  A charged second-site mutation in the fusion peptide rescues replication of a mutant avian sarcoma and leukosis virus lacking critical cysteine residues flanking the internal fusion domain.

Authors:  Deborah C Melder; Xueqian Yin; Sue E Delos; Mark J Federspiel
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

10.  Novel monoclonal antibody directed at the receptor binding site on the avian sarcoma and leukosis virus Env complex.

Authors:  Christina Ochsenbauer-Jambor; Sue E Delos; Mary Ann Accavitti; Judith M White; Eric Hunter
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.